These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 16556037

  • 1. Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
    Harrison CN.
    Future Oncol; 2005 Oct; 1(5):609-18. PubMed ID: 16556037
    [Abstract] [Full Text] [Related]

  • 2. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
    Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlögl E, Gisslinger H.
    Cancer; 2004 Nov 15; 101(10):2239-46. PubMed ID: 15476273
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders.
    Petitt RM, Silverstein MN, Petrone ME.
    Semin Hematol; 1997 Jan 15; 34(1):51-4. PubMed ID: 9025162
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
    Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A.
    Haematologica; 2003 Oct 15; 88(10):1130-8. PubMed ID: 14555309
    [Abstract] [Full Text] [Related]

  • 13. Anagrelide: 20 years later.
    Emadi A, Spivak JL.
    Expert Rev Anticancer Ther; 2009 Jan 15; 9(1):37-50. PubMed ID: 19105705
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
    Hultdin M, Sundström G, Wahlin A, Lundström B, Samuelsson J, Birgegård G, Engström-Laurent A.
    Med Oncol; 2007 Jan 15; 24(1):63-70. PubMed ID: 17673813
    [Abstract] [Full Text] [Related]

  • 17. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R, Adam H, Widmer L, Honegger HP.
    Schweiz Med Wochenschr; 1998 Nov 14; 128(46):1808-12. PubMed ID: 9857387
    [Abstract] [Full Text] [Related]

  • 18. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
    Silver RT.
    Leukemia; 2005 Jan 14; 19(1):39-43. PubMed ID: 15510207
    [Abstract] [Full Text] [Related]

  • 19. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
    Balduini CL, Bertolino G, Noris P, Ascari E.
    Haematologica; 1992 Jan 14; 77(1):40-3. PubMed ID: 1398280
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.